MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

Home・Elenco Azioni・Pulse Biosciences Inc

Pulse Biosciences Inc

Chiusa

SettoreSettore sanitario

13.75 -3.44

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

13.75

Massimo

14.24

Metriche Chiave
By Trading Economics
Entrata	-217K -19M
Vendite	86K 86K
EPS	-0.29
Margine di Profitto	-22,540.698
Dipendenti	75
EBITDA	-228K -19M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+54.39% upside

Dividendi
By Dow Jones
Utili prossimi	26 mar 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-179M 958M
Apertura precedente	17.19
Chiusura precedente	13.75

Notizie sul Sentiment di mercato

By Acuity

60%

40%

312 / 361 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

16.59 / 17.17 Supporto e resistenza

Pulse Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

20 gen 2026, 23:43 UTC

Discorsi di Mercato

Gold Consolidates; May Face Technical Correction -- Market Talk

20 gen 2026, 23:42 UTC

Discorsi di Mercato

Nikkei May Fall Amid Concerns Over U.S.-Europe Trade Relations -- Market Talk

20 gen 2026, 23:41 UTC

Utili

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- 2nd Update

20 gen 2026, 23:29 UTC

Discorsi di Mercato

RBA Rate Hike in February Would Be a Painful One -- Market Talk

20 gen 2026, 23:26 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

20 gen 2026, 23:26 UTC

Discorsi di Mercato

James Hardie Appeals More as Reece's U.S. Strategy Comes Under Scrutiny -- Market Talk

20 gen 2026, 22:45 UTC

Acquisizioni, Fusioni, Takeovers

ACCC: Ampol-EG Deal Is First Assessment Subject to Phase 2 Review Under New Merger Control Regime

20 gen 2026, 22:45 UTC

Acquisizioni, Fusioni, Takeovers

ACCC Seeks Submissions in Response to Phase 2 Notice by February 4

20 gen 2026, 22:44 UTC

Acquisizioni, Fusioni, Takeovers

ACCC: Ampol's Offer to Sell 19 Retail Fuel Sites Doesn't Adequately Address Issues

20 gen 2026, 22:44 UTC

Acquisizioni, Fusioni, Takeovers

ACCC Identifies 115 EG Sites Where Deal Could Substantially Lessen Competition

20 gen 2026, 22:43 UTC

Acquisizioni, Fusioni, Takeovers

ACCC Says Deal Could Substantially Lessen Competition in Retail Supply of Petrol, Diesel in Several Markets in Australia

20 gen 2026, 22:43 UTC

Acquisizioni, Fusioni, Takeovers

Ampol's Acquisition of EG Australia to Undergo In-Depth Review by Competition Regulator

20 gen 2026, 22:27 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Plans to Roll Out New Mobile User Interface Later This Year, Co-CEO Says

20 gen 2026, 22:25 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Co-CEO Sees Uptick in Engagement for TV-Based Games

20 gen 2026, 22:21 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Would Keep 45-Day Theater Release Window for Warner Bros. Films, Co-CEO Says

20 gen 2026, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Excited to Strengthen Warner Bros.'s Theatrical-Distribution Business, Co-CEO Says

20 gen 2026, 22:19 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Pleased With Early Results for Podcasts, Co-CEO Says

20 gen 2026, 22:18 UTC

Utili

Netflix Stock Is Falling. This Is Overshadowing the Streamer's Earnings Beat. -- Barrons.com

20 gen 2026, 22:17 UTC

Acquisizioni, Fusioni, Takeovers

Netflix's Live Events Are Boosting Retention, Co-CEO Says

20 gen 2026, 22:16 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Remains 'Very Excited' About Live-Events Offering, Co-CEO Says

20 gen 2026, 22:15 UTC

Acquisizioni, Fusioni, Takeovers

Netflix's Proposed Deal for Warner Bros. Would Protect, Create Jobs, Co-CEO Says

20 gen 2026, 22:15 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Competes for Attention Across Streaming, Broadcast, Cable, Gaming, Social Media, Video Platforms, Co-CEO Says

20 gen 2026, 22:13 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Co-CEO: TV Landscape Has Never Been More Competitive

20 gen 2026, 22:11 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Confident Warner Bros. Deal Would Pass Regulatory Review, Co-CEO Says

20 gen 2026, 22:10 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Would Leverage Global Footprint, Streaming Expertise to Improve Warner Bros.'s HBO Max Service, Co-CEO Says

20 gen 2026, 22:08 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Won't Raise Prices During Regulatory-Review Process for Pending Warner Bros. Deal, Co-CEO Says

20 gen 2026, 22:07 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Sees Warner Bros. as Another Mechanism to Improve Offerings, Co-CEO Says

20 gen 2026, 22:06 UTC

Utili

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- Update

20 gen 2026, 22:00 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

ESG Roundup: Market Talk

20 gen 2026, 21:50 UTC

Discorsi di Mercato

Utili

Tech, Media & Telecom Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Pulse Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

54.39% in crescita

Previsioni per 12 mesi

Media 22 USD 54.39%

Alto 22 USD

Basso 22 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Pulse Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 1 che hanno fornito valutazioni azionarie a Pulse Biosciences Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

16.59 / 17.17Supporto e resistenza

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

312 / 361 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Pulse Biosciences Inc

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.